Discover how the t(11;14) genetic flaw in multiple myeloma creates a unique vulnerability to the targeted therapy venetoclax through BCL-2 protein dependency.
Exploring a clinical trial combining panobinostat and carfilzomib for treating relapsed multiple myeloma with promising results.
A comprehensive analysis of four-drug versus three-drug regimens for newly diagnosed multiple myeloma, examining safety, efficacy, and clinical evidence.
Exploring the role of ErbB and insulin signaling pathways in multiple myeloma pathogenesis and their therapeutic implications.